Mirabegron in Parkinson Disease and Impaired Cognition
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack
of pharmacotherapies with an acceptable side effect profile. Specifically, available
anticholinergic medications have a high risk of cognitive side-effects, which preclude their
use in PD patients with CI. PD can also cause a number of non-motor symptoms that are likely
to be adversely affected by the currently available anticholinergic agents. Mirabegron is the
first pharmacologic treatment which may not exacerbate CI, constipation, orthostatic
hypotension (OH), somnolence, and dry mouth in PD.